Adetunji T Toriola1, Mark Ziegler2, Yize Li2, Michael Pollak3, Rachael Stolzenberg-Solomon4. 1. Department of Surgery, Division of Public Health Sciences, and Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA. a.toriola@wustl.edu. 2. Department of Surgery, Division of Public Health Sciences, and Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA. 3. Department of Oncology, McGill University, Montreal, Canada. 4. Branch of Nutritional Epidemiology, Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.
Abstract
BACKGROUND: Prediagnosis obesity and diabetes are associated with survival from pancreatic cancer, but the underlying mechanisms have not been characterized. Because both are associated with dysregulation in circulating insulin-like growth factor (IGF) levels, we evaluated the associations of prediagnosis IGF levels (IGF-I, IGF-II) and IGF binding protein 3 (IGFBP-3) with pancreatic cancer survival. METHODS: Participants were subjects enrolled in the intervention arm of the PLCO Cancer Screening Trial who developed exocrine pancreatic cancer during follow-up (N = 178, 116 men and 67 women). Participants provided blood samples at enrollment, before cancer diagnosis. Cox proportional hazards regression model, adjusted for confounders was used to investigate associations of IGF biomarkers with pancreatic cancer survival. Because of the well-documented, gender-specific differences in circulating IGF biomarkers, and differential associations of IGF biomarkers with mortality, we evaluated associations separately among males and females. RESULTS: Median survival was 172 days. Higher IGF-II and IGFBP-3 levels were associated with pancreatic cancer survival among males but not among females. The hazard ratios (HR) of death among men in the highest tertiles of IGF-II and IGFBP-3 compared with men in the lowest tertiles were 0.40 (95% confidence interval (CI) 0.23-0.71, p < 0.01) and 0.59 (95% CI 0.35-0.97, p = 0.10), respectively. There were no statistically significant associations between IGF-I concentrations, IGF-I/IGFBP-3, and pancreatic cancer survival. CONCLUSIONS: Higher prediagnosis circulating IGF-II and IGFBP-3 levels are associated with better pancreatic cancer survival among men but not women. A greater understanding of how IGF signaling is related to pancreatic cancer survival could have utility in improving pancreatic cancer prognosis.
BACKGROUND: Prediagnosis obesity and diabetes are associated with survival from pancreatic cancer, but the underlying mechanisms have not been characterized. Because both are associated with dysregulation in circulating insulin-like growth factor (IGF) levels, we evaluated the associations of prediagnosis IGF levels (IGF-I, IGF-II) and IGF binding protein 3 (IGFBP-3) with pancreatic cancer survival. METHODS:Participants were subjects enrolled in the intervention arm of the PLCO Cancer Screening Trial who developed exocrine pancreatic cancer during follow-up (N = 178, 116 men and 67 women). Participants provided blood samples at enrollment, before cancer diagnosis. Cox proportional hazards regression model, adjusted for confounders was used to investigate associations of IGF biomarkers with pancreatic cancer survival. Because of the well-documented, gender-specific differences in circulating IGF biomarkers, and differential associations of IGF biomarkers with mortality, we evaluated associations separately among males and females. RESULTS: Median survival was 172 days. Higher IGF-II and IGFBP-3 levels were associated with pancreatic cancer survival among males but not among females. The hazard ratios (HR) of death among men in the highest tertiles of IGF-II and IGFBP-3 compared with men in the lowest tertiles were 0.40 (95% confidence interval (CI) 0.23-0.71, p < 0.01) and 0.59 (95% CI 0.35-0.97, p = 0.10), respectively. There were no statistically significant associations between IGF-I concentrations, IGF-I/IGFBP-3, and pancreatic cancer survival. CONCLUSIONS: Higher prediagnosis circulating IGF-II and IGFBP-3 levels are associated with better pancreatic cancer survival among men but not women. A greater understanding of how IGF signaling is related to pancreatic cancer survival could have utility in improving pancreatic cancer prognosis.
Authors: Johan Svensson; Daniel Carlzon; Max Petzold; Magnus K Karlsson; Östen Ljunggren; Asa Tivesten; Dan Mellström; Claes Ohlsson Journal: J Clin Endocrinol Metab Date: 2012-09-26 Impact factor: 5.958
Authors: Jacqueline M Major; Gail A Laughlin; Donna Kritz-Silverstein; Deborah L Wingard; Elizabeth Barrett-Connor Journal: J Clin Endocrinol Metab Date: 2010-01-15 Impact factor: 5.958
Authors: Rachael Z Stolzenberg-Solomon; Paul Limburg; Michael Pollak; Philip R Taylor; Jarmo Virtamo; Demetrius Albanes Journal: Cancer Epidemiol Biomarkers Prev Date: 2004-03 Impact factor: 4.254
Authors: Nele Friedrich; Robin Haring; Matthias Nauck; Jan Lüdemann; Dieter Rosskopf; Elisabeth Spilcke-Liss; Stephan B Felix; Marcus Dörr; Georg Brabant; Henry Völzke; Henri Wallaschofski Journal: J Clin Endocrinol Metab Date: 2009-02-17 Impact factor: 5.958
Authors: Jared R Mayers; Chen Wu; Clary B Clish; Peter Kraft; Margaret E Torrence; Brian P Fiske; Chen Yuan; Ying Bao; Mary K Townsend; Shelley S Tworoger; Shawn M Davidson; Thales Papagiannakopoulos; Annan Yang; Talya L Dayton; Shuji Ogino; Meir J Stampfer; Edward L Giovannucci; Zhi Rong Qian; Douglas A Rubinson; Jing Ma; Howard D Sesso; John Michael Gaziano; Barbara B Cochrane; Simin Liu; Jean Wactawski-Wende; JoAnn E Manson; Michael N Pollak; Alec C Kimmelman; Amanda Souza; Kerry Pierce; Thomas J Wang; Robert E Gerszten; Charles S Fuchs; Matthew G Vander Heiden; Brian M Wolpin Journal: Nat Med Date: 2014-09-28 Impact factor: 53.440